TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›CGEN
CGEN logo

CGEN

COMPUGEN LTD

Next earnings Aug 4, 2026 · consensus $-0.08 EPS, $1.64M rev

Buy
$2.28
▲ +5.56%
$2.28▲ +37.35%
over 1Y
L $1.33H $3.10
Today+5.6%
1W+12.9%
1M+0.9%
3M+0.9%
YTD+47.1%
1Y+37.3%
OverviewFinancialsValuationQualityFilings
Rating
Buy
Quality
A
Valuation
Undervalued
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Strong Buy

Revenue grew 161.1% YoY.

Revenue (FY2025) $72.8M · FY2025

The read

Quality fundamentals and an attractive price line up (~533% below fair value) — the rarer case where both the business and the entry look good.

COMPUGEN LTD shows $72.8M in FY2025 revenue (+161.1% YoY), a 48.6% net margin, and 34.4% ROE.

Supporting the case: revenue grew 161.1% YoY; strong net margin (48.6%); high return on equity (34.4%); undemanding valuation (P/E 6.0).

Is CGEN a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bull call spread (wide)~60d expiry
  • Long call 2.5 @ ~0.15 est
  • Short call 2.5 @ ~0.15 est
debit $0max +$0max $0

High-conviction BUY: a wider spread keeps more of the upside while the short call still cuts cost and decay.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$6.00M$7.50M$33.5M$27.9M$72.8M
Gross profit$5.32M$6.53M$31.5M$19.9M$63.5M
Operating income-$35.1M-$35.4M-$13.0M-$14.9M$31.3M
Net income-$34.2M-$33.7M-$18.8M-$14.2M$35.3M
Diluted EPS-$0.41-$0.39-$0.21-$0.16$0.38
Net margin-570.0%-449.3%-56.1%-51.1%48.6%

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$125M
EV / EBITDA—
EV / Sales1.7
EV / FCF4.0
P / FCF6.9
PEG (trailing)0.02
Earnings yield16.4%
FCF yield14.5%

Quality & risk

ROIC (est.)24.1%
Free cash flow$31.3M
Total debt—
Net cash$90.6M
Piotroski F-Score6/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+5.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
EFFECTFiling2026-06-08open ↗F-3Filing2026-05-18open ↗6-KPeriod ending 2026-05-182026-05-18open ↗4Period ending 2026-04-242026-04-27open ↗4Period ending 2026-04-242026-04-27open ↗144Filing2026-04-27open ↗144Filing2026-04-27open ↗4Period ending 2026-04-142026-04-15open ↗4Period ending 2026-04-142026-04-15open ↗4/APeriod ending 2026-04-102026-04-15open ↗144Filing2026-04-15open ↗144Filing2026-04-15open ↗

Quality score

A
ValueGrowthProfitHealthMom.
ValueA-
GrowthA+
ProfitabilityA+
Financial healthA-
MomentumC+
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✓Net margin above 10%
  • ✓Return on equity above 15%
  • ✓P/E below 25

Fair value est.

$14.44

Undervalued +533% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.38 × (8.5 + 1.5 × 22.0% growth) × 1.16 quality = 38.0× multiple. An estimate, not a price target.

1.3352-week3.10
Revenue
$72.8M
+161.1% YoY
Net margin
48.6%
ROE
34.4%
P/E
6.0

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$72.8M+161.1%
Net income$35.3M+348.4%
Gross profit$63.5M+218.6%
Operating income$31.3M+310.4%
Diluted EPS$0.38+337.5%
Cash & equivalents$90.6M+397.0%
Total assets$157M+36.2%
Stockholders' equity$103M+87.1%
Gross: 87.3%Op.: 43.1%

Frequently asked

Is COMPUGEN LTD (CGEN) a buy?
CGEN currently carries a Buy rating with 5/5 conviction, derived from its latest SEC filings. Revenue grew 161.1% YoY.
What is CGEN's fair value?
A Modified-Graham model based on CGEN's SEC fundamentals estimates a fair value of about $14.44. It is an estimate from reported earnings, not a price target.
Is CGEN overvalued or undervalued?
Against a Modified-Graham fair-value estimate, CGEN currently appears undervalued relative to its SEC-grounded earnings power.
What is COMPUGEN LTD's quality score?
CGEN scores 84.7189265536723/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001119774, latest EFFECT filed 2026-06-08) · EODHD · as of 7/4/2026, 10:40:05 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:40 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 7 sales

2026-04-24
Levine Zurit
SVP, Business Development
Exercise2.00K @ $1.15$2.30K
2026-04-24
Levine Zurit
SVP, Business Development
Sell2.00K @ $3.20$6.40K
2026-04-24
Ophir Eran
President and CEO
Exercise5.00K @ $0.83$4.15K
2026-04-24
Ophir Eran
President and CEO
Sell5.00K @ $3.20$16.0K
2026-04-14
Ophir Eran
President and CEO
Exercise5.00K @ $0.83$4.15K
2026-04-14
Ophir Eran
President and CEO
Sell5.00K @ $2.90$14.5K
2026-04-14
Levine Zurit
SVP, Business Development
Exercise2.00K @ $1.15$2.30K
2026-04-14
Levine Zurit
SVP, Business Development
Sell2.00K @ $2.80$5.60K
2026-04-10
Levine Zurit
SVP, Business Development
Exercise1.13K @ $0.83$932.85
2026-04-10
Levine Zurit
SVP, Business Development
Exercise2.00K @ $1.15$2.30K
2026-04-10
Levine Zurit
SVP, Business Development
Sell3.13K @ $2.56$8.01K
2026-04-08
Levine Zurit
SVP, Business Development
Exercise4.38K @ $0.83$3.63K

Held by tracked funds

Form 13F · SEC · quarterly
ARK Investment ManagementCathie Wood1.05M sh$2.24M

As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score85 vs 67
Revenue growth161.1% vs 7.5%
Net margin48.6% vs 10.0%
Return on equity34.4% vs 12.0%
P/E6.0 vs 26.2